ADME Study in Healthy Male Subjects With TA-8995

Xention

Status and phase: Completed; Phase 1

Conditions: Dyslipidemia

Treatments: Drug: TA-8995

Study type: Interventional

Funder types: Industry

Identifiers

NCT02408055

TA-8995-07

Details and patient eligibility

About

A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.

Enrollment: 6 patients

Sex: Male

Ages: 30 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male subjects

Exclusion criteria

• Clinically significant abnormalities

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Radiolabelled TA-8995

Experimental group

Treatment:

Drug: TA-8995